Literature DB >> 16761317

TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation.

Anne Cottalorda1, Claire Verschelde, Antoine Marçais, Martine Tomkowiak, Philippe Musette, Satoshi Uematsu, Shizuo Akira, Jacqueline Marvel, Nathalie Bonnefoy-Berard.   

Abstract

TLR have a crucial role in the detection of microbial infection in mammals. Until recently, most investigations on TLR have focused on cells of the innate immune system and on the role of TLR in the initiation of antigen-specific responses following recognition of microbial products by APC. Here, we report that murine T cells express TLR1, TLR2, TLR6, TLR7 and TLR9 mRNA. Using CD8 T cells from F5 TCR-transgenic mice, we demonstrate that the lipopeptide Pam(3)CysSK(4) (Pam), a synthetic analog of bacterial and mycoplasmal lipoproteins that recognizes TLR1/2 complex, costimulates antigen-activated T cells. Costimulation with Pam permits an increased cell proliferation and survival associated with a sustained CD25 expression and an enhanced expression of Bcl-xL anti-apoptotic protein. In addition, we show that costimulation with Pam up-regulates IFN-gamma production but also granzyme B secretion and cytotoxic activity of antigen-activated T cells, indicating that TLR2 engagement enhances the major effector functions of CD8 T cells. Finally, we demonstrate that TLR2 engagement on T cells lowers the activation threshold for costimulatory signals delivered by APC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16761317     DOI: 10.1002/eji.200636181

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  89 in total

Review 1.  Plasticity in programming of effector and memory CD8 T-cell formation.

Authors:  Ramon Arens; Stephen P Schoenberger
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis.

Authors:  Sandra M Sacre; Evangelos Andreakos; Serafim Kiriakidis; Parisa Amjadi; Anna Lundberg; Grey Giddins; Marc Feldmann; Fionula Brennan; Brian M Foxwell
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Authors:  Deepak B Salunke; Nikunj M Shukla; Euna Yoo; Breanna M Crall; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2012-03-15       Impact factor: 7.446

4.  Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease.

Authors:  Joseph M Reynolds; Bhanu P Pappu; Juan Peng; Gustavo J Martinez; Yongliang Zhang; Yeonseok Chung; Li Ma; Xuexian O Yang; Roza I Nurieva; Qiang Tian; Chen Dong
Journal:  Immunity       Date:  2010-04-29       Impact factor: 31.745

5.  Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.

Authors:  Nikunj M Shukla; Subbalakshmi S Malladi; Cole A Mutz; Rajalakshmi Balakrishna; Sunil A David
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

6.  Expression and Function of TLR2 on CD4 Versus CD8 T Cells.

Authors:  Sun-Mi Lee; Young-Don Joo; Su-Kil Seo
Journal:  Immune Netw       Date:  2009-08-31       Impact factor: 6.303

Review 7.  The expression and functions of toll-like receptors in atherosclerosis.

Authors:  Jennifer E Cole; Ektoras Georgiou; Claudia Monaco
Journal:  Mediators Inflamm       Date:  2010-06-24       Impact factor: 4.711

8.  Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.

Authors:  Nicole Asprodites; Liqin Zheng; Degui Geng; Cruz Velasco-Gonzalez; Luis Sanchez-Perez; Eduardo Davila
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

9.  Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Authors:  Hari Prasad Kokatla; Euna Yoo; Deepak B Salunke; Diptesh Sil; Cameron F Ng; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Lauren M Fox; Sunil A David
Journal:  Org Biomol Chem       Date:  2013-02-21       Impact factor: 3.876

Review 10.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.